이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Recordati Industria Chimica e Farmaceutica 과거 수익 실적
과거 기준 확인 6/6
Recordati Industria Chimica e Farmaceutica은 연평균 1.4%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 수입이 증가했으며, 연간 8.4%였습니다. 매출은 연평균 9.2%의 비율로 증가했습니다. Recordati Industria Chimica e Farmaceutica의 자기자본이익률은 21.4%이고 순이익률은 18.2%입니다.
주요 정보
1.4%
수익 성장률
1.3%
EPS 성장률
| Pharmaceuticals 산업 성장 | 12.4% |
| 매출 성장률 | 9.2% |
| 자기자본 수익률 | 21.4% |
| 순이익 | 18.2% |
| 다음 실적 업데이트 | 30 Jul 2024 |
최근 과거 실적 업데이트
Recent updates
Estimating The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
May 26
Recordati Industria Chimica e Farmaceutica (BIT:REC) Will Pay A Larger Dividend Than Last Year At €0.63
May 10Recordati Industria Chimica e Farmaceutica's (BIT:REC) Dividend Will Be Increased To €0.63
Apr 25Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Share Price Could Signal Some Risk
Apr 23If EPS Growth Is Important To You, Recordati Industria Chimica e Farmaceutica (BIT:REC) Presents An Opportunity
Apr 08Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Increasing Its Dividend To €0.63
Mar 23Is Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Expensive For A Reason? A Look At Its Intrinsic Value
Jan 27We Think Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Stay On Top Of Its Debt
Jan 09Risks To Shareholder Returns Are Elevated At These Prices For Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Dec 22Recordati Industria Chimica e Farmaceutica (BIT:REC) Has Announced That It Will Be Increasing Its Dividend To €0.57
Nov 12Is Recordati Industria Chimica e Farmaceutica (BIT:REC) Using Too Much Debt?
Sep 29Estimating The Fair Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Sep 08Here's Why Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Manage Its Debt Responsibly
Jun 23Does This Valuation Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Imply Investors Are Overpaying?
Jun 05Recordati Industria Chimica e Farmaceutica's (BIT:REC) Conservative Accounting Might Explain Soft Earnings
Apr 08Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Increasing Its Dividend To €0.60
Apr 05Recordati Industria Chimica e Farmaceutica (BIT:REC) Has Announced That It Will Be Increasing Its Dividend To €0.60
Mar 19Here's Why Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Manage Its Debt Responsibly
Mar 06A Look At The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Dec 23Is Recordati Industria Chimica e Farmaceutica (BIT:REC) A Risky Investment?
Dec 05Recordati Industria Chimica e Farmaceutica (BIT:REC) Will Pay A Larger Dividend Than Last Year At €0.55
Nov 11Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Intrinsic Value Is Potentially 42% Above Its Share Price
Sep 01These 4 Measures Indicate That Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Using Debt Reasonably Well
Aug 07An Intrinsic Calculation For Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Suggests It's 25% Undervalued
Jun 03Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Paying Out A Larger Dividend Than Last Year
May 16Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Paying Out A Larger Dividend Than Last Year
May 02Recordati Industria Chimica e Farmaceutica's (BIT:REC) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 18Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Increasing Its Dividend To €0.57
Apr 04Recordati Industria Chimica e Farmaceutica (BIT:REC) Will Pay A Larger Dividend Than Last Year At €0.57
Mar 21These 4 Measures Indicate That Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Using Debt Reasonably Well
Mar 06Calculating The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Dec 22Recordati Industria Chimica e Farmaceutica (BIT:REC) Has A Pretty Healthy Balance Sheet
Dec 05Estimating The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Sep 23Is Recordati Industria Chimica e Farmaceutica (BIT:REC) A Risky Investment?
Sep 05A Look At The Fair Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Jun 25Here's Why Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Manage Its Debt Responsibly
Jun 07Earnings Miss: Recordati Industria Chimica e Farmaceutica S.p.A. Missed EPS By 8.5% And Analysts Are Revising Their Forecasts
May 10Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Shares Could Be 34% Above Their Intrinsic Value Estimate
Mar 11Here's What You Should Know About Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) 2.4% Dividend Yield
Feb 19Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Jan 30수익 및 비용 분석
수익 및 비용 분석
Recordati Industria Chimica e Farmaceutica 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
| 날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
|---|---|---|---|---|
| 31 Mar 24 | 2,139 | 389 | 608 | 263 |
| 31 Dec 23 | 2,082 | 389 | 602 | 256 |
| 30 Sep 23 | 2,032 | 375 | 600 | 247 |
| 30 Jun 23 | 2,005 | 389 | 601 | 240 |
| 31 Mar 23 | 1,985 | 340 | 601 | 237 |
| 31 Dec 22 | 1,853 | 312 | 572 | 220 |
| 30 Sep 22 | 1,801 | 331 | 546 | 202 |
| 30 Jun 22 | 1,702 | 330 | 517 | 184 |
| 31 Mar 22 | 1,615 | 393 | 489 | 168 |
| 31 Dec 21 | 1,580 | 386 | 481 | 166 |
| 30 Sep 21 | 1,511 | 377 | 459 | 160 |
| 30 Jun 21 | 1,460 | 365 | 442 | 156 |
| 31 Mar 21 | 1,404 | 334 | 417 | 153 |
| 31 Dec 20 | 1,449 | 355 | 422 | 146 |
| 30 Sep 20 | 1,475 | 389 | 431 | 144 |
| 30 Jun 20 | 1,499 | 391 | 438 | 141 |
| 31 Mar 20 | 1,528 | 388 | 452 | 135 |
| 31 Dec 19 | 1,482 | 369 | 446 | 130 |
| 30 Sep 19 | 1,439 | 328 | 428 | 122 |
| 30 Jun 19 | 1,399 | 322 | 414 | 116 |
| 31 Mar 19 | 1,369 | 318 | 405 | 111 |
| 31 Dec 18 | 1,352 | 312 | 401 | 110 |
| 30 Sep 18 | 1,338 | 307 | 400 | 108 |
| 30 Jun 18 | 1,333 | 306 | 400 | 107 |
| 31 Mar 18 | 1,313 | 297 | 399 | 105 |
| 31 Dec 17 | 1,288 | 289 | 397 | 100 |
| 30 Sep 17 | 1,255 | 275 | 391 | 96 |
| 30 Jun 17 | 1,217 | 262 | 385 | 89 |
| 31 Mar 17 | 1,194 | 250 | 380 | 85 |
| 31 Dec 16 | 1,154 | 237 | 369 | 84 |
| 30 Sep 16 | 1,126 | 229 | 363 | 82 |
| 30 Jun 16 | 1,096 | 218 | 357 | 80 |
| 31 Mar 16 | 1,074 | 212 | 355 | 79 |
| 31 Dec 15 | 1,048 | 199 | 352 | 77 |
| 30 Sep 15 | 1,030 | 190 | 350 | 79 |
| 30 Jun 15 | 1,019 | 181 | 349 | 82 |
| 31 Mar 15 | 1,003 | 170 | 344 | 84 |
| 31 Dec 14 | 987 | 161 | 341 | 85 |
| 30 Sep 14 | 982 | 156 | 338 | 81 |
| 30 Jun 14 | 972 | 146 | 334 | 77 |
| 31 Mar 14 | 957 | 139 | 333 | 77 |
| 31 Dec 13 | 942 | 134 | 330 | 75 |
| 30 Sep 13 | 910 | 127 | 320 | 74 |
양질의 수익: REC 은 높은 수익을 보유하고 있습니다.
이익 마진 증가: REC 의 현재 순이익 이익률 (18.2%) 작년보다 높습니다 (17.1%).
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: REC 의 수입은 지난 5년 동안 매년 1.4% 씩 증가했습니다.
성장 가속화: 지난 1년간 REC 의 수익 증가율( 14.5% )은 연간 평균( 1.4% 초과합니다. ).
수익 대 산업: 지난 1년간 REC 수익 증가율( 14.5% )은 Pharmaceuticals 업계 1.2% 초과했습니다.
자기자본 수익률
높은 ROE: REC 의 자본 수익률( 21.4% )은 높음으로 간주됩니다.